SUMMARY An Ashkenazi Jewish brother and sister developed progressive ataxia and proximal neurogenic muscle weakness, associated with supranuclear ophthalmoplegia, in the fourth decade of life. Hexosaminidase A activity, assayed using both synthetic and natural substrates, was severely reduced in the patients' plasma, leukocytes, and skin fibroblasts. Enzyme activity in their parents was in a similar range to that seen in heterozygotes for Tay-Sachs disease. The increasing evidence for marked clinical and molecular heterogeneity in the GM2 gangliosidoses warrants their consideration in the diagnosis of multisystem degenerative neurological disorders, even On examination, she spoke rapidly with a mixed cerebellar/bulbar dysarthria, and had a staring gaze. The fundi were normal. Voluntary upgaze was limited to 10% of normal, and horizontal and downgaze to about 80%. Pursuit improved the range of eye movements, to about 30% of normal on upgaze, but with some impersistence. The doll's head manoeuvre resulted in full horizontal movements and downgaze, and a further improvement in upgaze. Convergence was poor. Occasional facial twitching was seen, particularly around the left side of the mouth. There were brisk jaw, pout, and gag reflexes. Voluntary palatal and tongue movements were reduced. There was moderate wasting of the thighs with marked (MRC grade 3) weakness of all movements of the hips and knees. The knee jerks were absent but tapping the patellar tendons produced a brisk adductor response bilaterally; the other tendon reflexes were normal and the plantar responses were extensor. There was mild limb ataxia. Vibration sense was reduced below the knees but other sensory modalities were normal. The patient's gait was ataxic and waddling; she could not stand from sitting without using her arms. 687 group.bmj.com on June 16, 2017 -Published by 
The GM2 gangliosidoses result from genetically determined deficiencies of the enzyme hexosaminidase which cleaves the terminal Nacetylgalactosamine moiety from GM2 ganglioside. Hexosaminidase A deficiency was first recognised in patients with Tay-Sachs disease, a progressive infantile encephalopathy comprising progressive dementia associated with seizures and the macular cherry red spot.' In the last decade it has become apparent that the hexosaminidase deficiencies exhibit marked clinical and genetic heterogeneity. Neurological symptoms may develop in infancy, childhood, or adult life, with rapid or slow progression. Enor Table 1 shows the hexosaminidase activity found in plasma and leukocytes from both patients and their parents, and also in the patients' skin fibroblasts, using the synthetic 4-methyl-umbelliferyl substrate as described previously.3 Hexosaminidase A activity was markedly reduced in the patients, to the same extent as seen in cases of Tay-Sachs disease; in their parents activity was in the range seen in Tay-Sachs heterozygotes. Table 2 shows GM2 degradation in cultured skin fibroblasts from both patients, measured in Professor K Sandhoffs laboratory according to the method of Conzelmann and colleagues. 4 The rates observed were in the Tay-Sachs disease range in Case 2, and rather higher, similar to those found in other cases of juvenile and adult onset GM2 gangliosidosis, in Case 1. Electron microscopy of samples of skin from both patients, and muscle from Case 1, showed no intraneuronal inclusions.
Discussion
Normal hexosaminidase activity requires two major isozymes (hexosaminidases A and B), three gene loci, two kinds of subunits (alpha and beta, encoded for on chromosomes 15 and 5 respectively), and an activator protein. Hexosaminidase A is composed of both alpha and beta subunits, whereas hexosaminidase B consists only of beta chains. Mutations of the beta locus result in deficiencies of hexosaminidase A and B; the commonest phenotype is Sandhoff disease, an infantile encephalopathy, although cases with juvenile and adult onset have been described. 5 Deficiency of the activator protein gives rise to the "AB variant" of Tay-Sachs disease, but has also been described in a young adult with dementia, seizures, and communicating hydrocephalus.6 Classical infantile Tay-Sachs disease is caused by a mutation at the alpha locus2 which results in virtually undetectable activity of hexosaminidase A.' Patients with late infantile or juvenile onset variants of TaySachs disease have also been described.3 In the latter, affected children develop normally until about the age of four years, when gait ataxia and progressive dementia become apparent, associated with seizures and spasticity, leading to death in the second decade of life.
More chronic neurological disorders associated with hexosaminidase A deficiency have been reported in about 20 patients, a number of whom were identified during screening programmes for TaySachs disease carriers amongst the Ashkenazi Jewish population.7" Most of the cases described had a variable combination of cerebellar ataxia and neurogenic proximal muscle weakness, mainly affecting the legs, with ages of onset of symptoms ranging from two to 25 years. Other features included facial grimacing, psychosis, dystonia, dementia and, rarely, peripheral nerve involvement. In some patients the overall clinical picture has resembled that of amyo-689 trophic lateral sclerosis.'I The cases reported here are unusual in their late age of onset of symptoms, although in retrospect they admitted to lifelong clumsiness. The latter has been noted in previous reports.9 ' O A staring gaze and abnormal optokinetic nystagmus have been reported in hexosaminidase A deficiency;7 8 both of our patients had a more marked disorder of eye movements which appeared to be supranuclear in origin. Their rapid dysarthric speech was unusual and this has also been described by other authors. 7 9 The reason for the seemingly selective deleterious effect of ganglioside accumulation on the cerebellum, brainstem, and spinal cord is unclear, as is the case in most genetically determined neurodegenerative disorders. The CT scan appearances in our patients were particularly striking. Marked cerebellar atrophy, seen on magnetic resonance imaging, was also reported by Mitsumoto and colleagues" in two patients who were only mildly ataxic. Necropsy of one adult hexosaminidase A deficient patient revealed predominant GM2 storage and neuronal loss in the cerebellum and subcortical structures rather than in the cerebral cortex; the reverse occurs in infantile Tay-Sachs disease.'
The patients reported here had levels of hexosaminidase A activity similar to those seen in infantile Tay-Sachs disease when the enzyme was assayed using a synthetic substrate. Activity was higher with natural substrate in Case 1, about 12-5% of normal, as has been observed previously in deficient patients with later onset and less rapidly progressive neurological disability.'2 The relative increase in hexosaminidase B, which accounts for the normal total hexosaminidase activity, is usual in hexosaminidase A deficiency.
It is possible that our patients are compound heterozygotes for the Tay-Sachs disease gene and another mutation at the alpha locus; the four sibs described by Navon and colleagues9 were very similar to them clinically, and two of these had offspring with Tay-Sachs disease. Johnson2 suggested that the clinical complexity of the hexosaminidase deficiencies could be best understood if a parellel were drawn between them and the haemoglobinopathies, of which there are nearly 400. Multiple gene loci are involved in the synthesis of both haemoglobin and the hexosaminidase enzyme system. If the likely assumption is made that different mutations occur at the alpha and beta loci, and that at least some compound heterozygotes manifest neurological disease, it will be appreciated that the potential for clinical and genetic heterogeneity within hexosaminidase deficiency states is enormous. It is worth considering this diagnosis in patients with multisystem degenerative neurological disorders, even if onset is in adult life. Accurate diagnosis may have important implications for genetic counselling.
